Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Plasma-Cell Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00567229
What this trial is testing

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Memorial Sloan Kettering Cancer Center 3
Testing effectiveness (Phase 2)WithdrawnNCT03191981
What this trial is testing

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

Who this might be right for
Myeloma Multiple
University of Leeds
Large-scale testing (Phase 3)Active Not RecruitingNCT03319667
What this trial is testing

Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Who this might be right for
Plasma Cell Myeloma
Sanofi 475
Early research (Phase 1)Study completedNCT00761722
What this trial is testing

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromesLymphoma+2 more
Celgene 31
Not applicableEnrolling By InvitationNCT02473757
What this trial is testing

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

Who this might be right for
Lyphoma, B-CellLeukemia, B-cellMultiple Myeloma+1 more
National Cancer Institute (NCI) 1,000
Testing effectiveness (Phase 2)Study completedNCT02499081
What this trial is testing

UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

Who this might be right for
Multiple Myeloma
University of Arkansas 20
Not applicableStudy completedNCT03344328
What this trial is testing

Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.

Who this might be right for
Chemotherapy Induced Peripheral NeuropathyMultiple Myeloma
University Hospital, Clermont-Ferrand 67
Early research (Phase 1)Active Not RecruitingNCT05646836
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 90
Early research (Phase 1)Study completedNCT00996957
What this trial is testing

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Who this might be right for
Advanced Solid TumorsMultiple Myeloma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 37
Testing effectiveness (Phase 2)Looking for participantsNCT05091372
What this trial is testing

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Myeloma Multiple
M.D. Anderson Cancer Center 94
Not applicableStudy completedNCT03433001
What this trial is testing

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Takeda 295
Large-scale testing (Phase 3)Study completedNCT00004165
What this trial is testing

Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Northwestern University
Testing effectiveness (Phase 2)Active Not RecruitingNCT03455972
What this trial is testing

Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

Who this might be right for
Safety and Efficacy
The First Affiliated Hospital of Soochow University 43
Large-scale testing (Phase 3)Study completedNCT03595800
What this trial is testing

Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen

Who this might be right for
Acute LeukemiaNon Hodgkin LymphomaMultiple Myeloma
Institut Paoli-Calmettes 9
Post-approval studies (Phase 4)Ended earlyNCT03173092
What this trial is testing

Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Takeda 141
Testing effectiveness (Phase 2)Study completedNCT00317811
What this trial is testing

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Oncotherapeutics 35
Not applicableUnknownNCT04496011
What this trial is testing

Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation

Who this might be right for
FatigueLeukemiaLymphoma+2 more
Federal University of Health Science of Porto Alegre 30
Testing effectiveness (Phase 2)Study completedNCT03548207
What this trial is testing

JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 126
Testing effectiveness (Phase 2)WithdrawnNCT01101412
What this trial is testing

Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies

Who this might be right for
Chronic Myeloproliferative DisordersInfectionLeukemia+6 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00806767
What this trial is testing

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+3 more
Institut Paoli-Calmettes 82
Next Page